Abstract: An electric generator for use with a turbine (e.g. wind turbine) is disclosed. The generator comprises a stator and a rotor mounted for rotation with respect to the stator. The rotor comprises an even number M of magnets and the stator comprises an odd number C of coils. The number M of magnets and the number C of coils are chosen such that they do not have a common divider except 1. The coils are also generally made of a large number of turns of small wires such that each coil outputs high voltage but low current. In addition, the output of each one of the coils is generally rectified individually. An electric generator assembly is also disclosed. The generator of the invention is connected to a turbine, preferably a wind turbine, for rotating the rotor of the generator. A method for producing electricity is also disclosed.

Abstract: A length of conduit for encasing at least one electrical wire or cable, comprising two or more longitudinal conduit sections. Each longitudinal conduit section has two longitudinal edges formed with interlocking edge profiles shaped to engage with a snap fit with opposing longitudinal edge profiles of one or more other longitudinal conduit sections to form the conduit. Each conduit section also has one or more tabs or slots along the longitudinal edges to mate with tabs or slots on the other longitudinal conduit sections when brought together, to thereby substantially prevent relative longitudinal movement of the conduit sections. A longitudinal conduit section for use in forming the length of conduit is also described, which can be cut into two or more longitudinal conduit sub-sections and the sub-sections can be engaged to one another with a snap fit along the interlocking edge profiles to form a conduit.

Abstract: A concentrated solution of a wound healing promoter, in particular fibronectin, is used to develop solid wound dressings. The solid wound dressings containing fibronectin are easy to apply, easy to remove, and deliver fibronectin in a range of physiologically active dosages.

Abstract: This invention relates to the production of topical dosage forms containing human plasma fibronectin in combination with growth factors having human mitogenic or angiogenic activity, such as platelet-derived growth factor (PDGF-&bgr;&bgr;), to promote wound healing in humans.

Abstract: A deepithelialized skin cell diffusion system which can be used to select topical and cream formulations containing wound healing promoters such as plasma fibronectin. The formulations provide slow release and increased contact time of fibronectin or other wound healing promoters to the wound site leading to its effective absorption.

Abstract: Aqueous, non-buffered solutions containing high concentrations of fibronectin and other wound healing promoters are produced, which can then be used to make topical gel and cream formulations with high concentrations wound healing promoters. The formulations arc used for the healing of cutaneous wounds. The formulations provide slow release and increased contact time of fibronectin and of other wound healing promoters to the wound site leading to the effective absorption of the promoters.

Abstract: A deepithelialized skin cell diffusion system which can be used to select topical gel and cream formulations containing human other wound healing promoters such as plasma fibronectin. The formulations provide slow release and increased contact time of fibronectin or other wound healing promoters to the wound site leading to its effective absorption.

Abstract: A deepithelialized skin cell diffusion system which can be used to select topical gel and cream formulations containing human other wound healing promoters such as plasma fibronectin. The formulations provide slow release and increased contact time of fibronectin or other wound healing promoters to the wound site leading to its effective absorption.

Abstract: Topical gel and cream formulations containing human plasma fibronectin and other wound healing promoters are used for the healing of cutaneous wounds. The formulations provide slow release and increased contact time of fibronectin and of other wound healing promoters to the wound site leading to the effective absorption of the promoters.

Abstract: Topical gel and cream formulations containing human plasma fibronectin are used for the healing of cutaneous wounds. The formulations provide slow release and increased contact time of fibronectin to the wound site leading to effective absorption of an effective wound healing amount of fibronectin in the skin.